SPONSOR
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Total Trials
4
Recruiting
4
Phases
Phase 2, Phase 3
Conditions studied: Hepatocellular Carcinoma Non-resectableHCCHepatocellular CarcinomaMetastatic Colorectal CancerHepatocellular Carcinoma (HCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Hepatocellular Carcinoma Non-resectable, HCC, Hepatocellular Carcinoma, Metastatic Colorectal Cancer.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
How many clinical trials has Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, of which 4 are actively recruiting participants. These trials cover conditions including Hepatocellular Carcinoma Non-resectable, HCC, Hepatocellular Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest research focus on?
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest clinical trials span Hepatocellular Carcinoma Non-resectable, HCC, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Hepatocellular Carcinoma (HCC). The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest clinical trial?
To participate in a Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trials with current recruitment status updated daily.
Clinical Trials by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT04522544 Phase 2
Recruiting
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Hepatocellular Carcinoma Non-resectable
NCT04803994 Phase 3
Recruiting
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Hepatocellular Carcinoma
NCT06856837 Phase 2
Recruiting
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Metastatic Colorectal Cancer
NCT07365930
Recruiting
NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy
Hepatocellular Carcinoma (HCC)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology